Skip to main
GYRE

GYRE Stock Forecast & Price Target

GYRE Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Gyre Therapeutics Inc is positioned for positive financial growth through its strategic acquisition of generic nintedanib, which not only enhances its capital for operations but also solidifies its leadership in the idiopathic pulmonary fibrosis (IPF) market. This acquisition is deemed vital in challenging market conditions, reinforcing the company's capacity to offer a diverse range of therapies targeting both lung and liver fibrosis. Furthermore, Gyre's ongoing development of innovative drugs for conditions such as MASH fibrosis, alongside its existing commercial-stage products, suggests a robust pipeline that may drive significant future revenue.

Bears say

Gyre Therapeutics Inc. is currently facing a negative outlook primarily due to depressed forward multiples attributed to ongoing market volatility. The company's reliance on the commercial sales of pirfenidone in China, which has reached a plateau in revenue generation, also contributes to concerns about future growth potential. Additionally, cash burn poses a risk that could be exacerbated by the varying stages of development across its programs, highlighting uncertainties in revenue generation and operational sustainability.

GYRE has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gyre Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gyre Therapeutics Inc (GYRE) Forecast

Analysts have given GYRE a Strong Buy based on their latest research and market trends.

According to 2 analysts, GYRE has a Strong Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gyre Therapeutics Inc (GYRE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.